IMGN News and Press, ImmunoGen Inc.

Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...

2024-02-21 13:26:32 ET More on AbbVie AbbVie Q4: Now Isn't The Time To Buy My Largest Big Pharma Holding AbbVie: Game Changer AbbVie Q4 Review: Stock Remains A Buy, Encouraged By Skyrizi And Rinvoq AbbVie names Robert A. Michael as CEO and Richard A. Gonzalez...

2024-02-12 08:14:34 ET AbbVie ( NYSE: ABBV ) has updated its earnings outlook for the first quarter of 2024 to reflect a dilutive impact related to its acquisition of cancer drugmaker ImmunoGen ( NASDAQ: IMGN ).... Read the full article on Seeking Alpha For f...

AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...

2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-02-09 11:24:39 ET Summary AbbVie Inc. is set to finalize its deal for ImmunoGen, Inc. on February 12, with a small upside to the deal's closing price. The narrow spread and potential trading costs make it a reasonable decision to sell at this point. The yield on short-ter...

2024-02-09 09:45:09 ET Topdanmark A/S (TOP) TOP is trading UP for the last 5 days, and it at trading at $6.33 with volume of 47,351,282 and a one day change of $3.06 (93.54%). Topdanmark A/S has a 52-week low of 3.56 and a 52-week high of $256.44. The business's 50-day moving averag...

2024-02-08 08:30:45 ET More on ImmunoGen AbbVie: Risky Purchase Of ImmunoGen Could Pay Off Big Time Immunogen's AbbVie Deal: Key Insights For Investors And Traders AbbVie Bets Big On ImmunoGen: A $10 Billion Leap Into Ovarian Oncology AbbVie raised to Outperf...

2024-02-06 16:05:44 ET Summary AbbVie Inc. is showing signs of growth beyond the loss of exclusivity for Humira, with strong 2024 guidance. Sales of Skyrizi and Rinvoq are replacing lost Humira sales, with projected sales more than doubling through 2027. AbbVie's acquisitions ...

2024-02-04 12:00:49 ET More on AbbVie, Johnson & Johnson, etc. AbbVie Inc. (ABBV) Q4 2023 Earnings Call Transcript Merck & Co., Inc. 2023 Q4 - Results - Earnings Call Presentation Merck & Co., Inc. (MRK) Q4 2023 Earnings Call Transcript AbbVie cit...